THE MULTIFACETED BURDEN OF DEPRESSION: EXPLORING CAUSES, SYMPTOMS, AND TREATMENTS

Dr. Navinder Singh[1], Hemlata[2], Lalit Sharma[3]*, Rajnikant Yadav[4], Anoop[5]

[1,3,4,5]BM College of Pharmacy, Gurgaon, Haryana, India-122506
[2]Rajendera Institute of Technology Science, Sirsa, Haryana, India-125055
*Corresponding Author: Lalit Sharma
*BM College of Pharmacy, Gurgaon, Haryana, E-mail: lalitsharma92120@gmail.com

ABSTRACT

Depression, a pervasive and debilitating mental health disorder, affects millions of individuals worldwide, cutting across age, gender, and socioeconomic boundaries. The review begins with an overview of the global prevalence and incidence of depression, highlighting demographic variations and the significant impact of recent global events, such as the COVID-19 pandemic, on mental health. It then systematically examines the clinical definitions and classifications of depression, including major depressive disorder, dysthymia, and other subtypes, guided by diagnostic criteria from DSM-5 and ICD-11. The multifactorial etiology of depression is dissected into biological, psychological, and environmental contributors, emphasizing the interplay of genetic predispositions, neurotransmitter imbalances, cognitive theories, personality traits, and socio-environmental stressors. The review further explores the extensive spectrum of depression's impact, from emotional and psychological disturbances to physical symptoms and functional impairments in daily life, relationships, and comorbid mental health conditions. The challenges in diagnosing depression, the critical role of clinical interviews, psychometric tools, and the importance of distinguishing depression from other disorders are addressed. Treatment approaches are comprehensively analyzed, encompassing pharmacological therapies, psychotherapy, lifestyle interventions, complementary and alternative therapies, and emerging treatments such as ketamine therapy, TMS, and psychedelics. The review also discusses the pervasive challenges in treating depression, including stigma, accessibility, treatment adherence, and the risk of relapse. This extensive exploration underscores the need for a nuanced understanding of depression and a multifaceted approach to its treatment, paving the way for more effective, personalized, and accessible mental health care.

Keywords: Epidemiology, Diagnostic Criteria, Pharmacological Treatments, Psychotherapy, Emerging Treatments, Public Health Initiatives

INTRODUCTION

Depression is a common mental illness that affects people's mental, emotional, and physical well-being. Depression affects a person's thoughts, feelings, and ability to manage day-to-day tasks; it is distinguished by persistent sadness, a lack of hope, and disinterest in previously enjoyable activities. Depression, unlike fleeting emotions such as sadness or loss, can last for weeks, months, or even years. It can take various forms, including major depressive disorder (MDD), dysthymia, bipolar illness, and postpartum depression [1]. Each type of depression has unique features, but they all share common symptoms that disrupt normal functioning. Globally, depression is recognized as a leading cause of disability, with significant implications for personal well-being and public health.

Understanding depression is vital due to its far-reaching consequences on individuals, families, and communities [2]. Depression does not only affect mental health but also has physical health ramifications, increasing the risk for chronic diseases such as cardiovascular disease and diabetes. Additionally, depression can lead to severe outcomes, including suicidal ideation and suicide, which underscores the urgency of addressing this condition. The stigma surrounding depression often prevents individuals from seeking help, exacerbating the condition's severity and hindering recovery. By fostering a deeper understanding of depression, society can move toward more compassionate and effective approaches to treatment and support. This understanding also empowers healthcare providers to offer more personalized care, improving outcomes through early intervention, tailored treatment plans, and holistic care strategies. Moreover, understanding the multifactorial nature of depression—its roots in biology, psychology, and social context—allows for a more comprehensive approach to prevention and management. The scope of this review is extensive, covering multiple dimensions of depression to provide a well-rounded understanding of the disorder. It begins with an exploration of the epidemiology of depression, including its prevalence, demographic patterns, and risk factors. The review then delves into the neurobiological underpinnings of depression, discussing genetic predispositions, neurochemical imbalances, and the role of brain structures and networks. Psychological perspectives are also examined, including the impact of trauma, stress, and cognitive distortions on the development and perpetuation of depression. Treatment modalities are another focal point, encompassing both traditional approaches like antidepressant medications and cognitive-behavioral therapy, as well as emerging treatments such as transcranial magnetic stimulation (TMS) and psychedelic-assisted therapy [3]. The review also addresses the intersection of depression with other mental health conditions, such as anxiety and substance use disorders, and explores how these comorbidities complicate diagnosis and treatment. Finally, the review considers the broader societal and cultural context, analyzing how cultural attitudes, economic factors, and healthcare access influence the experience and management of depression. This comprehensive approach aims to provide a nuanced understanding of depression, offering insights that are relevant to both clinical practice and public health initiatives.

EPIDEMIOLOGY OF DEPRESSION

Depression is one of the most widespread mental health disorders globally, affecting more than 264 million people across all age groups. The prevalence of depression varies significantly across regions and cultures, influenced by socio-economic conditions, cultural attitudes toward mental health, and access to healthcare. In high-income countries, the lifetime prevalence of depression can reach up to 15%. In contrast, in low- and middle-income countries, the rate can be slightly lower but still significant, also depicted through **table 1** [4]. These figures highlight the universal nature of depression, emphasizing the need for global mental health initiatives and interventions. The occurrence of depression is not uniform across different demographic groups. Women are statistically more likely than men to suffer from depression, which can be explained by biological, hormonal, and psychological variables. Age also plays a critical role, with young adults and adolescents showing a rising trend in depression rates, often exacerbated by factors like social media use, academic pressures, and identity crises [5]. In contrast, older adults face depression due to factors like isolation, chronic illness, and loss of loved ones. Socioeconomic status further complicates the picture, with those in lower-income brackets facing higher risks of depression due to stressors like financial instability, lack of access to quality healthcare, and exposure to adverse living conditions. These demographic variations underline the importance of tailored approaches in diagnosing and treating depression. The COVID-19 pandemic has had a profound impact on mental health worldwide, leading to a surge in depression rates [6]. The pandemic-induced isolation, economic uncertainty, and fear of illness have contributed to a global mental health crisis. Studies have shown a significant increase in depression symptoms, particularly during lockdowns and periods of intense social distancing. The pandemic has also highlighted disparities in mental health care access, with vulnerable populations, such as frontline workers, those with pre-existing mental health conditions, and individuals living in pandemic hotspots, experiencing heightened levels of depression. The long-term implications of this surge in depression are still being studied, but the pandemic has undoubtedly

brought the issue of mental health to the forefront of public health discussions, emphasizing the need for enhanced mental health support systems.


Figure 1: Number of cases of depression in 20 different countries

TYPES OF DEPRESSION

Depression, also known as Major Depressive Disorder (MDD), is a complex mental illness with numerous components. Depression symptoms include a persistently low mood, a loss of interest in activities that used to bring you joy, and a variety of physical and cognitive issues that make it difficult to function in daily life. It is not merely a transient feeling of sadness or a reaction to life's challenges, but a profound disorder that affects how individuals think, feel, and manage daily activities [7]. Clinically, depression is recognized by its duration—symptoms must persist for at least two weeks—and its severity, which can range from mild to severe, potentially leading to an inability to perform basic self-care tasks. The disorder is often accompanied by feelings of hopelessness, worthlessness, and, in severe cases, thoughts of death or suicide. Depression's complexity is further compounded by its tendency to recur throughout a person's life, with each episode increasing the likelihood of future episodes, thus making it a chronic condition that requires long-term management. There are several clinical manifestations of depression, each with its own diagnostic criteria and set of distinguishing characteristics. The most common form of the disorder is Major Depressive Disorder (MDD). People with MDD usually have at least five of the symptoms listed in diagnostic manuals like the DSM-5. These symptoms include persistent feelings of worthlessness or excessive guilt, difficulty concentrating or thinking clearly, changes in appetite or weight, disrupted sleep, changes in psychomotor abilities, extreme exhaustion, and recurrent suicidal ideation [8]. Persistent Depressive Disorder (PDD), also known as dysthymia, is another form of depression. People with this disorder have a persistently low mood that lasts at least two years and is accompanied by at least two other depressive symptoms. While the symptoms may not be as severe as MDD, they can still be quite incapacitating if they persist over time. Bipolar disorder's symptomatology includes manic, hypomanic, and depressive episodes. Another type of depression, known as seasonal affective disorder (SAD), occurs in the winter when the days are shorter. This is most likely caused by fluctuations in serotonin levels and circadian rhythms [9]. Mothers, and to a lesser extent, men, can suffer from postpartum depression, a severe type of depression that appears after childbirth and is

characterised by overwhelming feelings of sorrow, worry, and fatigue. Extreme cases of premenstrual syndrome (PMS), known as premenstrual dysphoric disorder (PMDD), result in severe emotional and physical symptoms that interfere with daily life. Each type of depression requires a tailored approach to treatment, highlighting the importance of accurate diagnosis [10].

The diagnostic criteria for depression are primarily established by two major classification systems: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the International Classification of Diseases, Eleventh Revision (ICD-11). The DSM-5, published by the American Psychiatric Association, is widely used in the United States and other parts of the world and defines MDD by the presence of at least five symptoms from a specified list, including at least one of the core symptoms: depressed mood or anhedonia (loss of interest or pleasure) [11]. These symptoms must be present nearly every day for at least two weeks and cause significant distress or impairment in social, occupational, or other important areas of functioning. The ICD-11, published by the World Health Organization, is the international standard for reporting diseases and health conditions and provides a broader framework for diagnosing depression. It categorizes depression into different severity levels—mild, moderate, and severe—based on the number and severity of symptoms. The ICD-11 also takes into account the impact of symptoms on daily functioning and the presence of additional factors like anxiety [12]. Both systems require the exclusion of other possible causes, such as substance abuse or medical conditions, before a diagnosis of depression is confirmed. The diagnostic process is crucial for developing an effective treatment plan and requires a thorough assessment by a qualified mental health professional. The different types of depression and their diagnostic techniques are highlighted in **table 1**.

Table 1: Different types of depression and their diagnostic techniques.

Type of Depression	Description	Diagnostic Techniques	References
Major Depressive Disorder (MDD)	Symptoms include a loss of interest in previously enjoyed activities, as well as an overwhelming sense of sadness and despair that lasts for at least two weeks.	Clinical interviews, DSM-5 criteria, Beck Depression Inventory (BDI), Patient Health Questionnaire-9 (PHQ-9)	[13]
Persistent Depressive Disorder (Dysthymia)	An inferior type of MDD that lasts at least two years and has less severe symptoms.	DSM-5 criteria, Hamilton Depression Rating Scale (HAM-D), Clinical interviews	[14]
Bipolar Disorder (Bipolar Depression)	Involves alternating episodes of depression and mania/hypomania, with depressive episodes similar to MDD but typically part of a cyclical mood disorder.	DSM-5 criteria, Mood Disorder Questionnaire (MDQ), Structured Clinical Interview for DSM Disorders (SCID)	[15]
Postpartum Depression	A type of depression occurring following childbirth, characterized by severe mood swings, fatigue, and anxiety.	Edinburgh Postnatal Depression Scale (EPDS), DSM-5 criteria, Clinical interviews	[16]
Seasonal Affective Disorder (SAD)	Seasonal depressive disorder is associated with less sunlight and occurs primarily during the winter months.	DSM-5 criteria, Seasonal Pattern Assessment Questionnaire (SPAQ), Clinical interviews	[17]
Premenstrual Dysphoric	This is a severe case of premenstrual syndrome (PMS), which appears during the luteal	DSM-5 criteria, Premenstrual Symptoms	[18]

Disorder (PMDD)	phase of a woman's menstrual cycle as irritability, sadness, and significant mood swings.	Screening Tool (PSST), Clinical interviews	
Psychotic Depression	A type of major depressive disorder that is characterised by severe depression and psychosis, which may include hallucinations or delusions.	DSM-5 criteria, Clinical interviews, Psychotic Depression Assessment Tool (PDAT)	[19]
Atypical Depression	Depression that includes specific symptoms like increased appetite, excessive sleep, and sensitivity to rejection, differing from typical MDD symptoms.	DSM-5 criteria, Atypical Depression Diagnostic Scale (ADDS), Clinical interviews	[20]
Situational Depression (Adjustment Disorder)	Depression triggered by a specific life event or situation, causing symptoms similar to MDD but typically shorter in duration.	DSM-5 criteria, Adjustment Disorder New Module (ADNM), Clinical interviews	[21]
Disruptive Mood Dysregulation Disorder (DMDD)	A disorder characterised by excessive irritation, rage, and unreasonable and severe outbursts of temper that begin in infancy.	DSM-5 criteria, Clinical interviews, Child Behavior Checklist (CBCL), Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS)	[22]

BIOLOGICAL FACTORS

Hereditary variables have a strong influence on the onset of depression. According to studies, people who have a close relative with depression are more likely to develop the condition themselves. This genetic predisposition is linked to specific gene variations that regulate neurotransmitters and stress response systems. Twin studies have shown that the heritability of depression is approximately 40-50%, underscoring the importance of genetic factors in its etiology [23]. Because those with a genetic predisposition to depression are more easily triggered by stress and negative life experiences, the complex interaction of these genetic components and environmental variables complicates our understanding of depression. The molecular basis for depression is the presence or absence of several neurotransmitters, the most notable of which are serotonin, norepinephrine, and dopamine. Because these chemical messengers are necessary for mood regulation, disruptions in their levels or function may cause depressive symptoms. Serotonin, also known as the "feel-good" neurotransmitter, affects anxiety, mood, and overall emotional stability. Dopamine is involved in reward systems and pleasure, while norepinephrine is associated with energy and alertness [24]. Depression develops when there is an imbalance in certain neurotransmitters, which can be caused by hereditary factors, long-term stress, or other medical problems. This understanding has led to the development of pharmaceuticals such as selective serotonin reuptake inhibitors (SSRIs), which work by restoring neurotransmitter balance and relieving symptoms. Hormonal Effects: Hormonal abnormalities play an important role in the onset of depression. Depressed people frequently suffer from hypothalamic-pituitary-adrenal (HPA) axis disorders, which control the body's response to stress. Chronic stress can cause prolonged activation of the HPA axis, resulting in elevated levels of the stress hormone cortisol [25]. Hyperactivity can cause a decline in mood control abilities, including those of the prefrontal cortex and hippocampus. Additionally, hormonal changes associated with life events such as pregnancy, postpartum periods, and menopause can increase the risk of depression, particularly in women. The

role of thyroid hormones, which regulate metabolism and energy levels, is also significant, as hypothyroidism (low thyroid hormone levels) has been linked to depressive symptoms. Understanding these hormonal influences is crucial for developing targeted treatments and interventions for depression.

PSYCHOLOGICAL FACTORS

Cognitive theories of depression focus on the way individuals perceive, interpret, and think about their experiences. One of the most prominent theories, proposed by Aaron Beck, suggests that depression is rooted in a cognitive triad: negative views about oneself, the world, and the future. Individuals with depression often exhibit distorted thinking patterns, such as all-or-nothing thinking, overgeneralization, and catastrophizing [26]. These cognitive distortions lead to a pervasive sense of hopelessness and helplessness, which perpetuates the depressive state. Another significant cognitive theory is Martin Seligman's learned helplessness theory, which posits that individuals who have experienced uncontrollable negative events may develop a sense of helplessness, believing that they have no control over their circumstances. This belief system can lead to a passive acceptance of negative outcomes and a diminished motivation to seek positive change, thereby contributing to the development and maintenance of depression. Certain personality traits have been identified as risk factors for depression. Individuals with high levels of neuroticism, characterized by a tendency to experience negative emotions such as anxiety, anger, and sadness, are more susceptible to depression. Neuroticism is often associated with a heightened sensitivity to stress and an increased likelihood of perceiving situations as threatening or overwhelming [27]. Perfectionism is another personality trait that can contribute to depression, particularly when individuals set excessively high standards for themselves and struggle with self-criticism when these standards are not met. Introversion, characterized by a preference for solitude and a tendency to internalize emotions, can also increase vulnerability to depression, as it may limit social support and the expression of feelings. Understanding the role of these personality traits in depression is crucial for developing personalized interventions that address the unique psychological profiles of individuals.

Early life experiences, particularly those involving trauma and chronic stress, are significant psychological risk factors for depression. Abuse of any kind, whether physical, emotional, or sexual, as well as neglect or parental death, can have a significant and long-term impact on a child's mental development [28]. Some people who have been through trauma develop unhealthy coping strategies, such as numbing their emotions or being overly vigilant, which may increase their risk of developing depression in the future. Chronic stress experienced throughout childhood, such as family conflict, financial instability, or bullying, can also disrupt normal development and lead to the onset of depression. Changes in brain anatomy and function, particularly in regions responsible for emotion regulation and the stress response, help to mitigate the effects of stress and trauma during childhood. Furthermore, traumatic events in childhood can shape a person's outlook on life, causing them to develop deep-seated fears, doubts, and insecurities that may manifest as depression in later years. Addressing the psychological scars left by childhood trauma and stress is essential for effective treatment and prevention of depression.

ENVIRONMENTAL AND SOCIAL FACTORS

Socioeconomic challenges are significant environmental factors contributing to the development and persistence of depression. Individuals facing economic hardships, such as unemployment, poverty, or financial instability, often experience chronic stress, anxiety, and a sense of hopelessness, which can trigger or exacerbate depressive symptoms. The strain of not being able to meet basic needs, coupled with the stigma of financial difficulties, can lead to social withdrawal and a diminished sense of self-worth [29]. The impact of socioeconomic stressors is often intergenerational, affecting not just the individual but also their family dynamics, further entrenching the cycle of mental health issues. Research indicates that lower socioeconomic status is associated with a higher prevalence of depression, highlighting the need for systemic interventions that address economic inequalities as part of a comprehensive mental health strategy.

Interpersonal relationships play a crucial role in an individual's mental health, with relationship issues being a common trigger for depression. Conflicts within families, romantic relationships, or friendships can lead to feelings of rejection, loneliness, and emotional distress [30]. The breakdown of important relationships, such as through divorce, separation, or the loss of a loved one, can be particularly devastating, often leading to profound grief and depression. These emotional strains can result in a negative feedback loop where depressive symptoms further strain relationships, leading to social isolation and worsening of the condition. Abusive or toxic relationships, where one experiences emotional, physical, or psychological abuse, can erode self-esteem and sense of security, making individuals more vulnerable to depression. Addressing relationship issues through therapy, communication, and support systems is essential for mitigating the risk of depression [31].

Social isolation is a significant and well-documented risk factor for depression. Humans are inherently social beings, and the absence of meaningful social connections can lead to feelings of loneliness, worthlessness, and despair. Social isolation may be voluntary or involuntary, stemming from circumstances such as living alone, retirement, disability, or the loss of social networks due to life changes or relocations. The impact of social isolation is profound, as it not only affects emotional well-being but also has physical health implications, leading to a higher risk of chronic illnesses. The COVID-19 pandemic, with its lockdowns and social distancing measures, has exacerbated this issue, increasing the prevalence of depression globally [32]. Combatting social isolation through community engagement, social support networks, and fostering connections is crucial in preventing and addressing depression.

Emerging theories and models in the study of depression are expanding our understanding of this complex mental health condition beyond traditional frameworks. One such theory is the biopsychosocial model, which posits that depression is the result of the intricate interplay between biological, psychological, and social factors. This model emphasizes that no single factor alone can fully explain the onset or course of depression, highlighting the need for a holistic approach to treatment that considers all these dimensions. Another emerging perspective is the neuroinflammatory model, which suggests that inflammation in the brain, potentially triggered by stress, illness, or environmental toxins, may contribute to the development of depression by affecting neurotransmitter systems and brain function [33]. Additionally, the gut-brain axis is gaining attention, with research indicating that the microbiome and gut health may influence mood and behavior, suggesting that diet and gut microbiota could play a role in depression. These emerging theories underscore the importance of continued research to uncover the multifaceted nature of depression, leading to more targeted and effective interventions.

SYMPTOMS AND IMPACT OF DEPRESSION

Depression is primarily characterized by pervasive emotional and psychological symptoms that profoundly affect an individual's mental state. These symptoms often include persistent feelings of sadness, hopelessness, and emptiness, which are not easily alleviated by positive experiences or external circumstances. Individuals may experience a significant loss of interest or pleasure in activities that they once found enjoyable, a condition known as anhedonia. There may also be overwhelming feelings of guilt, worthlessness, or self-blame, even in the absence of any wrongdoing. Anxiety frequently accompanies depression, manifesting as excessive worry, restlessness, or feelings of impending doom [34]. Cognitive symptoms such as difficulty concentrating, indecisiveness, and impaired memory are also common, further complicating daily functioning and decision-making. In severe cases, these emotional and psychological symptoms can lead to thoughts of death, suicidal ideation, or suicide attempts, underscoring the critical need for timely and effective intervention. Depression is not only a mental health condition but also a disorder with significant physical manifestations. Individuals with depression often report a variety of somatic complaints, including chronic fatigue, low energy levels, and disturbances in sleep patterns, such as insomnia or hypersomnia. Appetite changes are also common, leading to significant weight loss or gain, depending on whether the individual experiences a loss of appetite or increased cravings for comfort foods [35]. Physical pain, such as headaches, muscle aches, and digestive problems, often accompanies depression, with no clear medical cause identified. These physical symptoms can

exacerbate the emotional distress of depression, creating a vicious cycle that further diminishes overall well-being. The presence of these somatic symptoms highlights the complex interplay between mind and body in depression, necessitating a comprehensive treatment approach that addresses both physical and mental health aspects. Depression severely impacts an individual's ability to function in daily life, leading to substantial impairments in both personal and professional domains. Those affected by depression may struggle with routine activities, such as maintaining personal hygiene, managing household tasks, or fulfilling responsibilities at work or school. The lack of motivation and energy often leads to procrastination, missed deadlines, and decreased productivity, which can result in disciplinary actions or job loss. Social withdrawal is another common feature, as individuals may avoid social interactions and isolate themselves due to overwhelming feelings of fatigue, anxiety, or worthlessness [36]. The impairment extends to cognitive functioning as well, with difficulties in concentration, memory, and decision-making that further hinder effective management of daily tasks. These functional impairments contribute to a diminished quality of life, perpetuating the cycle of depression and necessitating comprehensive therapeutic strategies to restore functional capacity and improve overall well-being. Depression exerts a profound impact on relationships and social life, often leading to strained interactions with family, friends, and colleagues. The emotional withdrawal and irritability commonly associated with depression can create misunderstandings and conflicts, as loved ones may misinterpret these behaviors as disinterest or hostility. The individual's lack of engagement and responsiveness in social settings can lead to a gradual erosion of social networks, fostering feelings of loneliness and exacerbating the depressive symptoms. In intimate relationships, depression can create significant challenges, including decreased communication, reduced physical intimacy, and increased dependency on the partner for emotional support, which can strain the relationship [37]. Furthermore, the stigma associated with mental illness may discourage individuals from seeking help or disclosing their condition to others, further isolating them from potential sources of support. Addressing the social and relational impact of depression is crucial, as strong social connections and supportive relationships are key components in the recovery process. Depression often coexists with other mental health disorders, a phenomenon known as comorbidity, which complicates both the diagnosis and treatment of the condition. Anxiety disorders, such as GAD, PA, and SAD, are among the most common co-occurring illnesses. Their symptoms frequently overlap and worsen those of depression. When people experience emotional distress, they may turn to substances as a coping mechanism. Substance use disorders, such as alcohol and drug abuse, frequently coexist with depression, resulting in a dual diagnosis that necessitates integrated treatment approaches. When depression is present alongside other mental health issues such as PTSD, anorexia, or personality disorders, the patient's clinical picture becomes more complicated, necessitating individualised treatment plans [38]. The presence of comorbid mental health disorders often results in more severe symptoms, greater functional impairment, and a higher risk of suicide, highlighting the need for comprehensive, multi-faceted treatment strategies that address the full spectrum of an individual's mental health needs.

DIAGNOSIS AND ASSESSMENT OF DEPRESSION

Clinical interviews are frequently used by mental health professionals as the first step in evaluating and diagnosing depression. These interviews are either fully or partially structured to provide a comprehensive picture of the patient's mental health, symptoms, and history. During these interviews, clinicians may learn about the patient's depressive symptoms, including frequency and severity. They can also assess how these symptoms affect the patient's ability to function in everyday life [39]. The doctor may also ask if there have been any triggering events, if you have a history of mental illness or a family history of the disorder, and if you have any physical health problems that are exacerbating the mental illness. Another aspect of conducting an interview is taking note of any suicidal thoughts, actions, or risk factors. When used in conjunction with interviews, depression severity questionnaires such as the Patient Health Questionnaire (PHQ-9) provide a standardised method for tracking changes over time and evaluating the effectiveness of treatment strategies [40]. Clinical interview and questionnaire data are used to create a specific and personalised treatment

plan.

Psychometric instruments are invaluable tools for diagnosing and evaluating depression because they provide objective and measurable assessments of depressive symptoms. The Beck Depression Inventory (BDI), a 21-item self-report questionnaire that assesses the severity of depression in both clinical and non-clinical populations, is one of the most widely used instruments [41]. Symptoms assessed by the BDI include mood, pessimism, self-dissatisfaction, guilt, punishment, self-dislike, suicidal ideation, crying, irritability, social withdrawal, indecision, body image, job difficulties, sleeplessness, exhaustion, hunger, weight loss, somatic obsession, and libido. A higher total score indicates more severe depression symptoms, with each item rated on a scale of 0-3. Psychometric instruments such as the BDI aid in diagnosis and therapy planning by allowing for both initial evaluation and tracking of changes in symptom intensity over time. These instruments are frequently used in conjunction with clinical interviews to provide a comprehensive picture of a patient's mental health.

One of the critical aspects of diagnosing depression is distinguishing it from other mental health disorders that may present with similar symptoms [42]. This process, known as differential diagnosis, requires careful evaluation and consideration of various factors. Conditions such as bipolar disorder, anxiety disorders, post-traumatic stress disorder (PTSD), and even certain medical conditions like hypothyroidism can exhibit symptoms overlapping with those of depression. For instance, bipolar disorder may include depressive episodes, but it is also characterized by manic or hypomanic episodes, which are absent in unipolar depression. Anxiety disorders, while frequently comorbid with depression, have distinct features such as excessive worry and panic attacks that need to be identified. PTSD may present with depression-like symptoms, but it is also associated with re-experiencing traumatic events, hyperarousal, and avoidance behaviors [43]. In differential diagnosis, clinicians must carefully analyze the symptomatology, course of illness, family history, and response to previous treatments to make an accurate diagnosis. Misdiagnosis can lead to inappropriate treatment, which underscores the importance of thorough and nuanced assessment.

Diagnosing depression can be fraught with challenges, owing to the complexity and variability of the disorder. Depression is a highly heterogeneous condition, with symptoms that can vary widely between individuals in terms of type, severity, and duration. Some individuals may present with classic symptoms of sadness and hopelessness, while others may exhibit irritability, anger, or somatic complaints as primary manifestations. The stigma surrounding mental illness can lead to underreporting or denial of symptoms, further complicating diagnosis. Cultural factors can influence the expression and interpretation of depressive symptoms, with some cultures more likely to somatize emotional distress. Co-occurring mental health disorders, such as anxiety, substance use disorders, or personality disorders, can obscure the clinical picture, making it difficult to isolate depression as the primary condition [44]. Furthermore, depression can sometimes be masked by or mistaken for medical conditions like chronic pain or neurodegenerative diseases. Misdiagnosis can occur because the symptoms of this ailment are similar to those of other medical and mental health conditions. A thorough evaluation is thus required. To correctly identify depression, clinicians must be aware of these issues and use a thorough evaluation method. Reduce diagnostic uncertainty by employing standardised diagnostic criteria, such as those outlined in the DSM-5 or ICD-11. Nonetheless, difficulties persist despite the availability of these resources [45]. The episodic nature of depression, where symptoms can fluctuate over time, adds another layer of complexity to diagnosis. For some individuals, symptoms may be mild and not meet the full criteria for Major Depressive Disorder, yet still significantly impair their quality of life, leading to a potential underdiagnosis. Conversely, in cases of mild depressive symptoms, there is a risk of overdiagnosis, especially when symptomatology is transient or related to situational stressors rather than an underlying depressive disorder. In the context of comorbidity, depression often coexists with other conditions such as anxiety, substance use disorders, and chronic physical illnesses. This comorbidity can obscure the primary diagnosis, making it challenging to determine whether depression is the primary disorder, a secondary condition, or part of a more complex psychological or medical profile. For instance, the presence of chronic pain or fatigue, common in conditions like fibromyalgia or chronic fatigue syndrome, can overlap with the somatic symptoms of depression, complicating the

diagnostic process. Additionally, the subjective nature of self-reported symptoms can pose a challenge. Patients may underreport symptoms due to stigma, lack of awareness, or fear of social repercussions, leading to potential underdiagnosis. On the other hand, patients who are highly attuned to their mental health or experiencing acute distress may overreport symptoms, leading to potential overdiagnosis or misdiagnosis [46]. Despite these challenges, accurate diagnosis is crucial for effective treatment. Misdiagnosis can result in inappropriate treatment strategies, which may exacerbate symptoms or lead to unnecessary side effects.

TREATMENT APPROACHES

Treating depression requires a multifaceted approach, with pharmacological treatments being a cornerstone of intervention strategies. These treatments are tailored to address the complex neurochemical imbalances and underlying biological factors that contribute to depressive disorders. The choice of medication, its dosage, and the overall treatment plan are typically personalized to meet the specific needs of each patient, considering factors such as the severity of symptoms, patient history, and potential side effects, as mentioned in **table 2**.

Treatment Approaches	Description	Examples and Techniques	Benefits	Limitations	References
Pharmacological Treatments	Use of medications to manage symptoms of depression by altering brain chemistry.	**Antidepressant Medications**: SSRIs (e.g., Fluoxetine, Sertraline), SNRIs (e.g., Venlafaxine), Tricyclic antidepressants (e.g., Amitriptyline)	Effective for many patients, can be tailored to individual needs, often necessary for severe cases.	Potential side effects, may take weeks to become effective, requires careful monitoring, not effective for everyone.	[47]
Psychotherapy and Counseling	Psychological treatment involving talking with a trained therapist to address emotional and psychological issues.	**Cognitive Behavioral Therapy (CBT)**: Identifying and changing negative thought patterns.	Helps patients understand their condition and develop coping strategies, can be long-lasting, no side effects associated with medication.	Requires time and commitment, may not be accessible to all due to cost or availability of trained therapists, effectiveness can vary based on the therapist and patient match.	[48]
Lifestyle Interventions	Changes to daily habits and lifestyle to support mental health.	**Exercise**: Regular physical activity to boost mood. **Diet and Nutrition**: Healthy eating habits. **Sleep Hygiene**: Improving sleep patterns.	Improves overall well-being, low cost, can be implemented alongside other treatments, empowers patients to take an active role in their recovery.	May not be sufficient as a standalone treatment for moderate to severe depression, requires motivation and consistency from the patient.	[49]
Complementary and Alternative Therapies	Non-conventional treatments used alongside or instead of traditional medical treatments.	**Mindfulness and Meditation**: Practices to increase awareness and manage stress. **Acupuncture**: Traditional Chinese medicine technique. **Herbal	Offers additional options for those not responding to traditional treatments, can be used to complement other therapies, often focuses on holistic well-being.	Limited scientific evidence for some approaches, not regulated, potential interactions with conventional medications, effectiveness varies widely among individuals.	[50]

		Remedies: Use of natural substances like St. John's Wort.			
Emerging and Experimental Treatments	New and innovative treatments that are being researched or newly introduced in clinical practice.	**Ketamine Therapy**: Rapid-acting antidepressant effects. **Transcranial Magnetic Stimulation (TMS)**: Non-invasive brain stimulation. **Psilocybin and Other Psychedelics**: Investigating the potential therapeutic effects of psychedelics under controlled conditions.	Promising options for treatment-resistant depression, some show rapid onset of effects, opens new avenues for research and understanding depression.	Still experimental with limited long-term data, potential side effects, regulatory and ethical concerns, accessibility issues, high costs.	[51]

PHARMACOLOGICAL TREATMENTS

Antidepressants are the most commonly prescribed pharmaceutical treatment for depression. The primary way they regulate mood, emotional response, and cognitive performance is by influencing neurotransmitter levels in the brain. These include norepinephrine, serotonin, and dopamine. Antidepressants that are commonly used include SSRIs, SNRIs, TCAs, and MAOIs, or selective serotonin reuptake inhibitors. Because of their effective antidepressant effects and low risk of side effects, selective serotonin reuptake inhibitors (SSRIs) such as citalopram, sertraline, and fluoxetine are commonly used as first-line treatments [52]. They improve mood regulation by increasing the availability of the neurotransmitter serotonin in the synaptic cleft while decreasing its reuptake into the presynaptic cell. SNRIs, like venlafaxine and duloxetine, have a similar mechanism but also affect norepinephrine levels, which can be beneficial for patients with certain types of depression, particularly those involving significant anxiety or physical pain symptoms. TCAs, including amitriptyline and nortriptyline, are older medications that are effective but often reserved for cases where newer antidepressants have not been successful due to their more pronounced side effects, such as drowsiness, weight gain, and anticholinergic effects. MAOIs, such as phenelzine and tranylcypromine, are also highly effective but require dietary restrictions and careful management due to potential interactions with other medications and foods containing tyramine, which can lead to hypertensive crises.

In addition to traditional antidepressants, adjunctive medications are sometimes prescribed to enhance treatment efficacy or target specific symptoms that are not adequately addressed by antidepressants alone [53]. These can include mood stabilizers, antipsychotic medications, and anxiolytics, which are often used in cases of treatment-resistant depression or when there is significant comorbidity with other mental health disorders, such as anxiety disorders or bipolar disorder. Mood stabilizers like lithium or anticonvulsants such as lamotrigine may be added to prevent mood swings and stabilize emotional states, particularly in patients with depressive episodes associated with bipolar disorder. Atypical antipsychotics, such as aripiprazole and quetiapine, are increasingly used as adjuncts to antidepressants, especially in cases where there are residual symptoms of depression or when psychotic features are present [54]. These medications can help in augmenting the antidepressant effect and improving overall treatment outcomes. Moreover, benzodiazepines or other anxiolytic medications may be used temporarily to alleviate severe anxiety

or insomnia that often accompanies depression, although these are typically prescribed with caution due to the risk of dependence and potential for abuse.

PSYCHOTHERAPY AND COUNSELLING

Psychotherapy and counseling are foundational components of the treatment of depression, offering individuals the tools to understand and manage their symptoms in a supportive and structured environment. These approaches are designed to address the psychological, emotional, and behavioral aspects of depression, providing both immediate relief and long-term coping strategies. Among the most widely utilized forms of psychotherapy for depression are Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), and other therapeutic modalities that are tailored to meet the specific needs of the patient [55].

CBT is one of the most extensively researched and empirically supported forms of psychotherapy for depression. CBT is based on the cognitive model, which posits that dysfunctional thinking patterns and maladaptive behaviors are central to the development and maintenance of depressive symptoms [56]. The therapy focuses on identifying and challenging these negative thought patterns, which are often automatic and deeply ingrained, and replacing them with more realistic and balanced ways of thinking. In CBT, patients work collaboratively with a therapist to explore the connections between their thoughts, emotions, and behaviors. Through various techniques, such as cognitive restructuring, patients learn to recognize cognitive distortions, such as catastrophizing, overgeneralization, and all-or-nothing thinking, which contribute to their depressive symptoms. By reframing these thoughts, patients can reduce the intensity of their negative emotions and begin to engage in more adaptive behaviors. Behavioral activation is another key component of CBT, where patients are encouraged to participate in activities that are likely to improve their mood and overall functioning. This approach is based on the understanding that depression often leads to a cycle of inactivity and withdrawal, which can further exacerbate symptoms [57]. By gradually increasing engagement in pleasurable or meaningful activities, patients can break this cycle and experience a sense of achievement and positive reinforcement. CBT is typically structured, goal-oriented, and time-limited, making it an appealing option for many patients. It provides practical skills that patients can use beyond the therapy sessions, which helps in preventing relapse and maintaining long-term mental health. The efficacy of CBT has been demonstrated across various populations and settings, making it a cornerstone in the psychological treatment of depression.

Interpersonal Therapy (IPT) is another evidence-based therapeutic approach that has been shown to be effective in treating depression. IPT is grounded in the idea that interpersonal relationships and life events significantly influence an individual's mood and emotional well-being. The therapy focuses on identifying and resolving interpersonal issues that may be contributing to the depressive symptoms, such as unresolved grief, role transitions, role disputes, and interpersonal deficits [58]. IPT is typically conducted over a short-term period, often 12 to 16 weeks, and is structured around the identification of a specific problem area that is most relevant to the patient's current depressive episode. For example, if a patient is struggling with unresolved grief, the therapy would focus on helping the patient process their loss and develop new ways of coping. If the issue is a role transition, such as a divorce or job loss, the therapy would help the patient adapt to the new circumstances and find new sources of support and fulfilment. The therapeutic process in IPT involves exploring the patient's interpersonal interactions and communication patterns, identifying areas where these may be contributing to the depressive symptoms, and working collaboratively to develop more effective and satisfying ways of relating to others. The therapist provides guidance, feedback, and support as the patient works through these issues, intending to reduce depressive symptoms and improve overall functioning. IPT's focus on interpersonal relationships makes it particularly effective for individuals whose depression is closely linked to social or relational difficulties. It helps patients build stronger, more supportive relationships, which can serve as a buffer against future depressive episodes.

Depression treatment options extend beyond cognitive behavioural therapy (CBT) and interpersonal therapy (IPT), with each method offering a unique perspective and set of tools that can be customised for each patient. The goal of psychodynamic therapy is to help patients understand how their unconscious thoughts and experiences influence their current emotions and actions [59]. This type

of treatment aims to identify and address any underlying emotional conflicts or problems that may be exacerbating depressive symptoms. Self-reflection and insight can help patients better understand and resolve their emotional world and inner problems. Mindfulness-Based Cognitive Treatment (MBCT) is another approach that combines mindfulness techniques with traditional cognitive therapy. Mindfulness-based cognitive therapy (MBCT) teaches patients to change their relationship with their thoughts by becoming more present-moment aware of their sensations and ideas without passing judgement [60]. For those who experience depression on a regular basis, this method has proven to be a valuable tool in the fight against relapse. Dialectical Behaviour Therapy (DBT) can help people with emotional dysregulation and self-destructive behaviours when they are depressed. Dialectical behaviour therapy (DBT) teaches patients how to control their emotions, strengthen their relationships, and reduce self-harm by combining cognitive-behavioral techniques with mindfulness and acceptance practices. Finally, the goal of humanistic therapy, which includes techniques such as Gestalt therapy and person-centred therapy, is to help patients achieve their full potential and develop their own distinct personality traits [61]. These treatments emphasise the client-therapist relationship, introspection, and the client's natural abilities for growth and recovery.

LIFESTYLE INTERVENTIONS

Exercise and physical activity are increasingly recognized as powerful tools in the management and treatment of depression. The physiological and psychological benefits of regular exercise are well-documented, with a significant body of research demonstrating that physical activity can effectively reduce symptoms of depression, often rivalling the efficacy of traditional pharmacological treatments. Exercise is believed to improve depression by modulating the body's neurochemical environment, enhancing the production of neurotransmitters such as serotonin, dopamine, and norepinephrine, which play key roles in mood regulation [62]. Beyond its neurochemical effects, exercise also promotes neurogenesis—the formation of new neurons—in areas of the brain such as the hippocampus, which is typically reduced in individuals suffering from depression. Regular physical activity can also reduce inflammation, a condition often linked with depressive symptoms. From a psychological perspective, exercise enhances self-efficacy, improves body image, and provides a sense of accomplishment, all of which contribute to an uplift in mood and overall mental well-being. Engaging in physical activity serves as a distraction from negative thought patterns, breaking the cycle of rumination that is common in depression. Group activities, such as team sports or group fitness classes, can also provide social support, reducing the feelings of isolation that often accompany depressive episodes. Incorporating regular exercise into a treatment plan for depression can be as simple as encouraging patients to start with low-intensity activities, such as walking or yoga, and gradually increasing the intensity and duration as they become more comfortable [63].

Diet and nutrition are important but often overlooked components of a comprehensive approach to treating depression. The "gut-brain axis," which connects a healthy digestive system to a healthy mind, has received a lot of attention in recent years [64]. A diet high in whole foods like fruits, vegetables, whole grains, and lean meats can provide essential nutrients that promote brain health and cognitive function. Fish, such as salmon and mackerel, as well as almonds and flaxseeds, contain omega-3 fatty acids, which may help reduce inflammation and depression symptoms. Inadequate levels of these fatty acids, which are required for brain development and function, have been linked to an increased incidence of mood disorders. Folate, serotonin, and B vitamins (particularly B6, B12, and B6) are all required for the production of these neurotransmitters [65]. A lack of certain vitamins can cause an imbalance in these important mood-regulating substances, potentially exacerbating depression. The study of how the gut microbiota affects mental health is still in its early stages. A healthy gut microbiota can positively influence mood and emotional well-being. This goal can be achieved by eating a well-balanced diet rich in probiotics (found in fermented foods, yoghurt, and kefir) and prebiotics (found in fiber-rich foods like fruits, vegetables, and legumes). Inflammation and oxidative stress caused by a high intake of processed foods, refined carbohydrates, and bad fats have been linked to the development and progression of depression. A nutrient-dense diet, in addition to supporting physical health, is an important component in the treatment of depression, when combined with other therapeutic methods. Sleep hygiene refers to the practices and habits conducive

to sleeping well regularly. For individuals with depression, sleep disturbances are common, manifesting as insomnia, hypersomnia, or disrupted sleep patterns, all of which can exacerbate depressive symptoms [66]. Establishing and maintaining good sleep hygiene is therefore a critical component of depression treatment. The relationship between sleep and depression is bidirectional: depression can lead to sleep problems, and sleep problems can contribute to or worsen depression. Poor sleep quality affects the body's circadian rhythms and can lead to imbalances in neurotransmitters and hormones such as melatonin and cortisol, which regulate mood and stress responses. Improving sleep hygiene involves several strategies, including maintaining a regular sleep schedule, creating a restful sleep environment, and minimizing exposure to screens and bright lights before bedtime. It also involves avoiding stimulants such as caffeine and nicotine in the hours leading up to sleep and engaging in relaxing activities, such as reading or taking a warm bath, to signal to the body that it is time to wind down.Behavioral interventions, such as Cognitive Behavioral Therapy for Insomnia (CBT-I), have been shown to be effective in treating sleep disturbances in individuals with depression. CBT-I focuses on changing sleep habits and challenging the thoughts and behaviors that contribute to poor sleep. By improving sleep quality and duration, patients can experience a reduction in depressive symptoms, as better sleep restores the body's natural rhythms and promotes emotional stability [67]. Mindfulness and meditation have recently gained popularity as alternatives to pharmaceutical depression treatments. Among these techniques is the practice of nonjudgmental awareness of one's internal and external experiences, such as thoughts, feelings, and body sensations. Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR) are two organised programs that use mindfulness practices in conjunction with cognitive-behavioral strategies to treat depression symptoms [68]. Mindfulness and meditation are effective tools for depression treatment because they help patients overcome the negative thought pattern known as rumination. Mindfulness helps to reduce the impact of negative thought and emotion patterns on mood and behaviour by teaching people to see these aspects of themselves objectively and without becoming caught up in them. Scientists have demonstrated that mindfulness and meditation can change brain structure and function. This is especially true in brain regions responsible for emotion regulation, such as the amygdala and prefrontal cortex. Increased grey matter density in these areas, linked to regular practice, is thought to result in improved emotional resilience and fewer depressive symptoms. Incorporating mindfulness and meditation into a daily routine can be as simple as practicing deep breathing exercises, body scans, or guided meditation sessions. Over time, these practices can help individuals develop a more balanced and accepting attitude toward their experiences, leading to a reduction in the intensity and frequency of depressive episodes [69].

Acupuncture and herbal remedies represent complementary and alternative medicine (CAM) approaches that have been explored for their potential benefits in treating depression. Acupuncture, a practice rooted in traditional Chinese medicine, involves the insertion of thin needles into specific points on the body to restore the flow of "qi" (energy) and balance the body's systems [70]. Acupuncture is believed to stimulate the release of endorphins and other neurochemicals that can help alleviate pain and improve mood. Some studies suggest that acupuncture may be as effective as antidepressant medications for certain individuals, particularly when used in combination with other treatments. It is thought to influence the autonomic nervous system and promote relaxation, thereby reducing the stress and anxiety often associated with depression. Herbal remedies, such as St. John's Wort, have also been used to treat depression, particularly in mild to moderate cases. St. John's Wort is believed to increase the levels of serotonin, dopamine, and norepinephrine in the brain, similar to the action of conventional antidepressants [71]. However, the use of herbal remedies should be approached with caution, as they can interact with other medications and may not be suitable for all individuals. Other herbs and supplements, such as saffron, omega-3 fatty acids, and SAMe (S-adenosylmethionine), have shown promise in alleviating depressive symptoms. However, the evidence for their efficacy varies, and more research is needed to fully understand their role in depression treatment. It is important for individuals considering these remedies to consult with a healthcare provider to ensure safety and appropriateness within the context of their overall treatment plan.

EMERGING AND EXPERIMENTAL TREATMENTS

The landscape of depression treatment is continually evolving, with emerging and experimental therapies offering new hope for individuals who have not responded to traditional approaches. These novel treatments include Ketamine Therapy, Transcranial Magnetic Stimulation (TMS), and the use of Psilocybin and Other Psychedelics. Each of these approaches leverages cutting-edge science to address the complexities of depression, providing innovative options for those seeking alternatives to conventional methods. Ketamine therapy represents one of the most groundbreaking advancements in the treatment of depression, particularly for individuals with treatment-resistant depression [72]. Originally developed as an anesthetic, ketamine has gained attention for its rapid-acting antidepressant effects, which can be observed within hours or days, compared to the weeks or months required for traditional antidepressants. Ketamine works primarily by blocking the N-methyl-D-aspartate (NMDA) receptor, a type of glutamate receptor in the brain [73]. This action increases the release of glutamate, a neurotransmitter involved in synaptic plasticity and neural communication. By enhancing synaptic connectivity in brain regions that regulate mood and emotion, such as the prefrontal cortex, ketamine can quickly alleviate depressive symptoms, including suicidal ideation. The administration of ketamine typically occurs in a controlled medical setting, where it is given as an intravenous infusion. A related compound, esketamine, has been approved by the FDA for use as a nasal spray, offering a more accessible form of the treatment. Despite its promise, ketamine therapy is not without risks, including potential for abuse and long-term effects that are not yet fully understood. Therefore, it is generally reserved for individuals who have not found relief through other treatment options. Transcranial magnetic stimulation (TMS), a non-invasive neurostimulation therapy, has shown promise in treating individuals with depression who have not responded to antidepressant medication [74]. Transcranial magnetic stimulation (TMS) targets several brain regions, including the left dorsolateral prefrontal cortex, which is frequently inactive in depressed people. Transcranial magnetic stimulation (TMS) involves pressing an electromagnetic coil against the patient's scalp to send brief magnetic pulses to a specific area of the brain. These pulses, which produce electrical currents that alter neuronal activity, improve the connectivity and communication of the brain's mood-controlling networks. The treatment is typically administered over several weeks, with sessions lasting around 20 to 40 minutes. TMS is valued for its relatively mild side effect profile compared to other treatments, with the most common being mild scalp discomfort or headaches. Importantly, TMS does not require anesthesia, and patients can return to their normal activities immediately after each session [75]. While TMS is a significant advancement in depression treatment, it is most effective in patients with moderate to severe depression and is less effective for those with certain comorbid psychiatric conditions.

Psilocybin and other psychedelics, such as LSD and MDMA, are gaining attention as potential treatments for depression, particularly for those who have not responded to traditional therapies. Psilocybin, the active compound in "magic mushrooms," is being studied for its ability to produce profound changes in consciousness and emotional processing, which can lead to enduring reductions in depressive symptoms [76]. Psychedelics are believed to exert their effects by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor. This interaction can result in a temporary dissolution of the ego, a heightened sense of connectedness, and altered perceptions of reality, which may help individuals reframe negative thought patterns and gain new insights into their mental health. Clinical trials have shown that psilocybin, when administered in a controlled setting with psychological support, can produce rapid and sustained antidepressant effects, even after just one or two sessions. These effects are thought to be mediated by changes in brain plasticity and connectivity, particularly in regions associated with mood regulation, such as the default mode network. The use of psychedelics in depression treatment is still experimental, and these substances are currently classified as Schedule I drugs in many countries, indicating a high potential for abuse and no accepted medical use [77]. As such, psychedelic-assisted therapy is conducted under strict clinical supervision, and its safety and efficacy continue to be the subject of extensive research.

CHALLENGES AND BARRIERS

Stigma surrounding mental health, particularly depression, remains one of the most significant barriers to effective treatment. Despite growing awareness, societal attitudes often label individuals with depression as weak, unmotivated, or even a burden, fostering an environment where sufferers may feel ashamed or reluctant to seek help. This stigma can be both internalized, leading individuals to downplay or deny their symptoms, and external, where societal judgment leads to discrimination in social, educational, and occupational settings [78]. The pervasive stigma attached to depression can result in delays in seeking treatment, as individuals may fear being ostracized or misunderstood by peers, family, and even healthcare professionals. The stigma is not just a cultural issue but can also be institutional, where inadequate mental health education and resources in healthcare systems contribute to underdiagnosis and undertreatment. Changing these attitudes requires comprehensive public health campaigns, education, and a shift in cultural narratives to normalize mental health discussions and encourage openness [79]. The accessibility and availability of depression treatment are often limited by geographic, economic, and systemic factors, creating significant barriers to care. In many parts of the world, especially in low- and middle-income countries, mental health services are severely underfunded and understaffed, leading to a scarcity of trained professionals and treatment facilities. Even in wealthier nations, disparities in healthcare access persist, often influenced by socioeconomic status, insurance coverage, and rural versus urban location. The high cost of treatment, including therapy sessions, medications, and associated care, can be prohibitive for many individuals, particularly those without adequate insurance or financial resources. This economic barrier is compounded by long wait times for appointments, limited availability of specialized care, and the logistical challenges of reaching healthcare facilities, especially in rural areas. Telemedicine and online therapy platforms have emerged as potential solutions to improve accessibility, yet they are not without challenges, including digital literacy, privacy concerns, and the need for a stable internet connection [80]. Addressing these accessibility issues requires systemic changes in healthcare policy, funding, and infrastructure, alongside efforts to integrate mental health services into primary care to reach underserved populations more effectively. Adherence to treatment plans is a critical yet challenging aspect of managing depression, significantly impacting the effectiveness of interventions. Adherence refers to the extent to which patients follow prescribed treatments, including taking medications as directed, attending therapy sessions, and engaging in recommended lifestyle changes [81]. However, adherence can be compromised by several factors, including the nature of depression itself. Depression often manifests with symptoms like fatigue, lack of motivation, and cognitive impairments, which can hinder an individual's ability to consistently adhere to treatment regimens. Side effects from antidepressant medications, such as weight gain, sexual dysfunction, or gastrointestinal issues, can also deter patients from continuing their medication. Additionally, the delayed onset of antidepressant efficacy, where benefits may take weeks to become noticeable, can lead to frustration and discontinuation.

Psychological factors, such as a lack of perceived need for treatment, doubts about its effectiveness, or fear of dependency, can further reduce adherence [82]. The complexities of treatment, including the need for regular follow-up appointments, therapy sessions, and lifestyle adjustments, can overwhelm patients, especially without a strong support system. Enhancing adherence requires a collaborative approach involving patient education, simplified treatment regimens, supportive relationships with healthcare providers, and, where possible, involving family members in the treatment process to provide encouragement and oversight. Relapse and recurrence of depressive episodes pose substantial challenges in the long-term management of depression. Depression is often a chronic, recurrent condition, with many individuals experiencing multiple episodes throughout their lives. Relapse refers to the return of depressive symptoms during the recovery phase or after remission, while recurrence denotes the onset of a new depressive episode after a period of recovery [83]. The risk of relapse and recurrence is influenced by several factors, including the severity and duration of the initial episode, comorbid mental health disorders, ongoing stressors, and the presence of residual symptoms after treatment. Inadequate or incomplete treatment, such as premature discontinuation of medication or therapy, also significantly increases the likelihood of relapse. Long-term maintenance strategies, such as continued medication, ongoing therapy, and lifestyle modifications, are often necessary to reduce the risk of relapse. These require sustained patient

engagement and monitoring, which can be difficult to maintain over time. The cyclical nature of depression, where periods of improvement are followed by setbacks, can be discouraging for both patients and their families, impacting treatment adherence and overall quality of life [84]. To address relapse and recurrence, it is crucial to adopt a proactive approach that includes regular follow-up, early identification of warning signs, and timely intervention. Psychoeducation for patients and their support networks, along with personalized treatment plans that evolve based on the individual's changing needs, can help mitigate the risk of relapse and support sustained recovery.

FUTURE DIRECTIONS

The future of pharmacotherapy in depression treatment is poised for significant advancements, driven by a deeper understanding of the neurobiological mechanisms underlying the disorder. Traditional antidepressants, such as SSRIs and TCAs, while effective for many, are often associated with delayed onset of action, limited efficacy in a subset of patients, and a range of side effects that can hinder adherence. Innovations in pharmacotherapy aim to address these limitations through the development of novel compounds that target new pathways and mechanisms in the brain [85]. Emerging treatments, such as ketamine and its derivatives (e.g., ketamine), have shown rapid antidepressant effects, offering hope for those with treatment-resistant depression. These agents work through the glutamatergic system, particularly by antagonizing the N-methyl-D-aspartate (NMDA) receptor, which represents a significant shift from the monoaminergic mechanisms targeted by traditional antidepressants [86]. Research into other novel targets, such as the modulation of the hypothalamic-pituitary-adrenal (HPA) axis, neuroinflammation, and neurogenesis, is also ongoing, with the potential to yield treatments that are both faster-acting and more effective across a broader range of patients.

Pharmacogenomics, which studies the role of genes in medication response, is another promising frontier for depression treatment. By tailoring antidepressant therapy to an individual's genetic profile, pharmacogenomics has the potential to enhance treatment efficacy, minimize side effects, and reduce the trial-and-error approach currently common in depression management [87]. This personalized medicine approach could revolutionize how depression is treated, making it possible to predict which medications will be most effective for a given individual.

Psychotherapy remains a cornerstone in the treatment of depression, with ongoing research aimed at refining existing techniques and developing new approaches to better address the diverse needs of patients. CBT and IPT have long been established as effective treatments, but there is growing interest in therapies that can integrate multiple modalities or that offer novel approaches to understanding and treating depression [88]. Third-wave cognitive therapies, such as Acceptance and Commitment Therapy (ACT) and Mindfulness-Based Cognitive Therapy (MBCT), are gaining traction for their focus on acceptance, mindfulness, and cognitive flexibility, rather than just symptom reduction. These therapies aim to help individuals develop a healthier relationship with their thoughts and emotions, fostering resilience and long-term mental well-being. Research into these approaches is expanding, with studies suggesting that they may be particularly effective in preventing relapse and promoting sustained recovery.

The demand for more accessible, scalable, and patient-centred care is propelling the rapid growth of technology's role in depression diagnosis and treatment. Following the COVID-19 epidemic, which highlighted the importance of remote healthcare treatments, telemedicine has become an indispensable tool. Through telemedicine, patients can access therapy and consultations from the comfort of their homes, reducing barriers related to geographic location, mobility, and stigma. Beyond telemedicine, mental health apps are increasingly being used as adjuncts to traditional treatment, offering a range of services from symptom tracking and mood monitoring to guided meditations and cognitive exercises. These apps can provide real-time feedback, personalized interventions, and ongoing support, helping individuals manage their symptoms between therapy sessions. Artificial intelligence (AI) and machine learning are also being integrated into these platforms to enhance the precision and personalization of care, using algorithms to analyze data and provide tailored recommendations [89]. In addition to improving access to care, technology is also playing a role in enhancing diagnostic accuracy. Digital phenotyping, which involves the use of data

from smartphones, wearables, and other digital devices to monitor behavior and physiological states, offers a new way to identify early signs of depression and track treatment progress. These technologies can capture data on sleep patterns, physical activity, social interactions, and other indicators, providing a more comprehensive and objective assessment of an individual's mental health status.

As the understanding of depression continues to evolve, there is a growing emphasis on preventive strategies and public health initiatives aimed at reducing the incidence and impact of the disorder. Prevention in mental health involves a multi-faceted approach, targeting risk factors at the individual, community, and societal levels [90]. This includes promoting mental health literacy, reducing stigma, and creating environments that support mental well-being. Public health initiatives are increasingly focused on early intervention, recognizing that timely support can prevent the progression of mild or moderate depression into more severe forms. School-based mental health programs, workplace wellness initiatives, and community outreach efforts are being implemented to educate individuals about the signs and symptoms of depression and to provide resources for those at risk. These initiatives often involve collaborations between healthcare providers, educators, employers, and policymakers to create a supportive infrastructure for mental health care. People are increasingly realising that socioeconomic determinants of mental health—issues such as poverty, prejudice, and a lack of educational and occupational opportunities—must be addressed as part of any successful prevention strategy. A comprehensive approach to preventing depression must include policies that promote social justice, provide housing and financial assistance, and ensure access to high-quality healthcare [91]. There is increasing interest in lifestyle interventions, such as promoting physical activity, healthy eating, and social connectedness, as preventive measures for depression. These interventions not only support overall health but also have specific benefits for mental well-being, reducing the risk of depression and enhancing resilience to stress and adversity.

CONCLUSION

This review underscores the global prevalence and significant public health burden of depression, which continues to rise, exacerbated by societal challenges and recent global crises. Understanding the wide-ranging causes and risk factors of depression, from genetic and neurobiological underpinnings to the profound impacts of early life stressors and ongoing environmental stress, is crucial for developing effective interventions. The review highlights the diverse spectrum of symptoms associated with depression, including emotional, psychological, and physical manifestations, all of which contribute to substantial functional impairments in individuals' daily lives and relationships. Diagnosing depression remains a complex task, complicated by overlapping symptoms with other mental health disorders and the subjective nature of many diagnostic criteria. In addressing treatment, the review emphasizes the necessity of personalized and integrated care approaches that combine pharmacological interventions with psychotherapy, lifestyle modifications, and emerging therapies. Despite significant advances in treatment, challenges such as societal stigma, barriers to access, and issues with treatment adherence persist, highlighting the need for ongoing public health efforts and policy reforms. The future of depression treatment and research looks promising, with innovative pharmacotherapies, advances in psychotherapeutic techniques, and the integration of technology poised to revolutionize care. Preventive strategies and public health initiatives also play a critical role in mitigating the impact of depression, emphasizing the importance of early intervention and mental health promotion across all age groups and communities. In conclusion, this review calls for continued research, enhanced public awareness, and a commitment to developing and implementing more effective, comprehensive strategies for managing and ultimately reducing the global burden of depression.

REFERENCES

1. Kessler RC, Berglund P, Demler O. Mood disorders: Bipolar and major depressive disorders. Jama. 2003;289(23):3095-105.

2. World Health Organization. The World Health Report 2001: Mental health: new understanding, new hope.

3. Larrea A, Sánchez-Sánchez L, Diez-Martin E, Elexpe A, Torrecilla M, Astigarraga E, Barreda-Gómez G. Mitochondrial metabolism in major depressive disorder: from early diagnosis to emerging treatment options. Journal of Clinical Medicine. 2024 Mar 17;13(6):1727.

4. Kazdin AE, Wu CS, Hwang I, Puac-Polanco V, Sampson NA, Al-Hamzawi A, Alonso J, Andrade LH, Benjet C, Caldas-de-Almeida JM, De Girolamo G. Antidepressant use in low-middle-and high-income countries: a World Mental Health Surveys report. Psychological medicine. 2023 Mar;53(4):1583-91.

5. Twenge JM, Joiner TE, Rogers ML, Martin GN. Increases in depressive symptoms, suicide-related outcomes, and suicide rates among US adolescents after 2010 and links to increased new media screen time. Clinical psychological science. 2018 Jan;6(1):3-17.

6. Stein DJ, Shoptaw SJ, Vigo DV, Lund C, Cuijpers P, Bantjes J, Sartorius N, Maj M. Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration. World Psychiatry. 2022 Oct;21(3):393-414.

7. Karp DA. Speaking of sadness: Depression, disconnection, and the meanings of illness. Oxford University Press; 2017.

8. Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: Implications for clinical practice and research of changes from DSM-IV. Depression and anxiety. 2014 Jun;31(6):459-71.

9. Magnusson A, Boivin D. Seasonal affective disorder: an overview. Chronobiology international. 2003 Jan 1;20(2):189-207.

10. Youngstrom EA, Choukas-Bradley S, Calhoun CD, Jensen-Doss A. Clinical guide to the evidence-based assessment approach to diagnosis and treatment. Cognitive and Behavioral Practice. 2015 Feb 1;22(1):20-35.

11. Kennedy SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in clinical neuroscience. 2008 Sep 30;10(3):271-7.

12. Kogan CS, Stein DJ, Maj M, First MB, Emmelkamp PM, Reed GM. The classification of anxiety and fear-related disorders in the ICD-11. Depression and anxiety. 2016 Dec;33(12):1141-54.

13. Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF. Major depressive disorder. Nature reviews Disease primers. 2016 Sep 15;2(1):1-20.

14. Schramm E, Klein DN, Elsaesser M, Furukawa TA, Domschke K. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. The Lancet Psychiatry. 2020 Sep 1;7(9):801-12.

15. Kessler RC, Berglund P, Demler O. Mood disorders: Bipolar and major depressive disorders. Jama. 2003;289(23):3095-105.

16. Stewart DE, Vigod S. Postpartum depression. New England Journal of Medicine. 2016 Dec 1;375(22):2177-86.

17. Melrose S. Seasonal affective disorder: an overview of assessment and treatment approaches. Depression research and treatment. 2015;2015(1):178564.

18. Itriyeva K. Premenstrual syndrome and premenstrual dysphoric disorder in adolescents. Current problems in pediatric and adolescent health care. 2022 May 1;52(5):101187.

19. Dubovsky SL, Ghosh BM, Serotte JC, Cranwell V. Psychotic depression: diagnosis, differential diagnosis, and treatment. Psychotherapy and psychosomatics. 2021 Apr 20;90(3):160-77.

20. Angst J, Gamma A, Benazzi F, Silverstein B, Ajdacic–Gross V, Eich D, Rössler W. Atypical depressive syndromes in varying definitions. European archives of psychiatry and clinical neuroscience. 2006 Feb;256:44-54.

21. Tennant C. Life events, stress and depression: a review of recent findings. Australian & New Zealand Journal of Psychiatry. 2002 Apr;36(2):173-82.

22. Rao U. DSM-5: disruptive mood dysregulation disorder. Asian Journal of Psychiatry. 2014 Oct 1;11:119-23.

23. Thapar A, Rice F. Twin studies in pediatric depression. Child and Adolescent Psychiatric Clinics. 2006 Oct 1;15(4):869-81.

24. Moret C, Briley M. The importance of norepinephrine in depression. Neuropsychiatric disease and treatment. 2011 May 31;7(sup1):9-13.

25. Gądek-Michalska A, Spyrka J, Rachwalska P, Tadeusz J, Bugajski J. Influence of chronic stress on brain corticosteroid receptors and HPA axis activity. Pharmacological Reports. 2013 Sep 1;65(5):1163-75.

26. Mercan N, Bulut M, Yüksel Ç. Investigation of the relatedness of cognitive distortions with emotional expression, anxiety, and depression. Current Psychology. 2023 Jan;42(3):2176-85.

27. Borja SE, Callahan JL, Rambo PL. Understanding negative outcomes following traumatic exposure: The roles of neuroticism and social support. Psychological Trauma: Theory, Research, Practice, and Policy. 2009 Jun;1(2):118.

28. Dye H. The impact and long-term effects of childhood trauma. Journal of Human Behavior in the Social Environment. 2018 Apr 3;28(3):381-92.

29. Inglis G, Jenkins P, McHardy F, Sosu E, Wilson C. Poverty stigma, mental health, and well-being: A rapid review and synthesis of quantitative and qualitative research. Journal of Community & Applied Social Psychology. 2023 Jul;33(4):783-806.

30. Canary DJ, Cupach WR, Messman S. Relationship conflict: Conflict in parent-child, friendship, and romantic relationships. Sage Publications; 1995 Aug 23.

31. Lieberman A. Counseling issues: Addressing behavioral and emotional considerations in the treatment of communication disorders. American journal of speech-language pathology. 2018 Feb 6;27(1):13-23.

32. Chiesa V, Antony G, Wismar M, Rechel B. COVID-19 pandemic: health impact of staying at home, social distancing and 'lockdown'measures—a systematic review of systematic reviews. Journal of public health. 2021 Sep;43(3):e462-81.

33. García-Bueno B, Caso JR, Leza JC. Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neuroscience & Biobehavioral Reviews. 2008 Aug 1;32(6):1136-51.

34. Lakhera KP. Anxiety-A theoretical analysis. Quest-The Journal of UGC-HRDC Nainital. 2018;12(3):241-6.

35. Rogers PJ, Smit HJ. Food craving and food "addiction": a critical review of the evidence from a biopsychosocial perspective. Pharmacology Biochemistry and Behavior. 2000 May 1;66(1):3-14.

36. Biordi DL, Nicholson NR. Social isolation. Chronic illness: Impact and intervention. 2013:97-132.

37. Bodenmann G, Meuwly N, Germann J, Nussbeck FW, Heinrichs M, Bradbury TN. Effects of stress on the social support provided by men and women in intimate relationships. Psychological science. 2015 Oct;26(10):1584-94.

38. Brady KT, Killeen TK, Brewerton T, Lucerini S. Comorbidity of psychiatric disorders and posttraumatic stress disorder. Journal of clinical psychiatry. 2000 Jan 1;61:22-32.

39. Williams Jr JW, Noël PH, Cordes JA, Ramirez G, Pignone M. Is this patient clinically depressed?. Jama. 2002 Mar 6;287(9):1160-70.

40. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Medical care. 2004 Dec 1;42(12):1194-201.

41. Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Brazilian Journal of Psychiatry. 2013 Oct;35:416-31.

42. Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. American journal of psychiatry. 2003 Jan 1;160(1):4-12.

43. Radell ML, Hamza EA, Moustafa AA. Depression in post-traumatic stress disorder. Reviews in the Neurosciences. 2020 Oct 25;31(7):703-22.

44. Iqbal MN, Levin CJ, Levin FR. Treatment for substance use disorder with co-occurring mental illness. FOCUS, A Journal of the American Psychiatric Association. 2019 Apr;17(2):88-97.

45. Clark LA, Cuthbert B, Lewis-Fernández R, Narrow WE, Reed GM. Three approaches to understanding and classifying mental disorder: ICD-11, DSM-5, and the National Institute of

Mental Health's Research Domain Criteria (RDoC). Psychological Science in the Public Interest. 2017 Nov;18(2):72-145.

46. Suhr J, Wei C. Attention deficit/hyperactivity disorder as an illness identity: Implications for neuropsychological practice. InNeuropsychological evaluation of somatoform and other functional somatic conditions 2017 Mar 16 (pp. 251-273). Routledge.

47. Kumar KS, Srivastava S, Paswan S, Dutta AS. Depression-symptoms, causes, medications and therapies. The Pharma Innovation. 2012 May 1;1(3, Part A):37.

48. Fusco GM, Apsche J. Cognitive behavioral therapy. Comparative treatments for borderline personality disorder. 2005:75-104.

49. Briguglio M, Vitale JA, Galentino R, Banfi G, Zanaboni Dina C, Bona A, Panzica G, Porta M, Dell'Osso B, Glick ID. Healthy eating, physical activity, and sleep hygiene (HEPAS) as the winning triad for sustaining physical and mental health in patients at risk for or with neuropsychiatric disorders: considerations for clinical practice. Neuropsychiatric disease and treatment. 2020 Jan 8:55-70.

50. Matos LC, Machado JP, Monteiro FJ, Greten HJ. Understanding traditional Chinese medicine therapeutics: an overview of the basics and clinical applications. InHealthcare 2021 Mar 1 (Vol. 9, No. 3, p. 257). MDPI.

51. Shanok NA, Muzac S, Brown L, Barrera M, Rodriguez R. Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study. Psychopharmacology. 2024 Mar 12:1-7.

52. Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. Journal of occupational and environmental medicine. 2008 Apr 1;50(4):428-36.

53. Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert review of neurotherapeutics. 2009 Jul 1;9(7):975-84.

54. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. Journal of Psychiatric Practice®. 2008 Jan 1;14(1):34-44.

55. Carter JD, Luty SE, McKenzie JM, Mulder RT, Frampton CM, Joyce PR. Patient predictors of response to cognitive behaviour therapy and interpersonal psychotherapy in a randomised clinical trial for depression. Journal of affective disorders. 2011 Feb 1;128(3):252-61.

56. Cristea IA, Huibers MJ, David D, Hollon SD, Andersson G, Cuijpers P. The effects of cognitive behavior therapy for adult depression on dysfunctional thinking: A meta-analysis. Clinical psychology review. 2015 Dec 1;42:62-71.

57. Jacobson NS, Martell CR, Dimidjian S. Behavioral activation treatment for depression: returning to contextual roots. Clinical Psychology: science and practice. 2001;8(3):255.

58. Brakemeier EL, Frase L. Interpersonal psychotherapy (IPT) in major depressive disorder. European archives of psychiatry and clinical neuroscience. 2012 Nov;262:117-21.

59. Stadter M. Presence and the present: Relationship and time in contemporary psychodynamic therapy. Jason Aronson; 2011 Dec 21.

60. Bihari JL, Mullan EG. Relating mindfully: A qualitative exploration of changes in relationships through mindfulness-based cognitive therapy. Mindfulness. 2014 Feb;5:46-59.

61. Malchiodi CA. Humanistic approaches. Handbook of art therapy. 2003:58-71.

62. Pahlavani HA. Possible role of exercise therapy on depression: effector neurotransmitters as key players. Behavioural brain research. 2023 Dec 2:114791.

63. Otto M, Smits JA. Exercise for mood and anxiety: Proven strategies for overcoming depression and enhancing well-being. Oxford University Press; 2011 Jul 28.

64. Skonieczna-Żydecka K, Marlicz W, Misera A, Koulaouzidis A, Łoniewski I. Microbiome—the missing link in the gut-brain axis: focus on its role in gastrointestinal and mental health. Journal of clinical medicine. 2018 Dec 7;7(12):521.

65. Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, Lorenzl S, Linnebank M. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert review of neurotherapeutics. 2009 Sep 1;9(9):1393-412.

66. Mendlewicz J. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. The World Journal of Biological Psychiatry. 2009 Jan 1;10(4):269-75.

67. Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cellular and Molecular Life Sciences. 2007 May;64:1174-86.

68. Wagner C, Cáceres-Melillo R. Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR) in the treatment of Post-Traumatic Stress Disorder (PTSD): A literature review. Salud mental. 2023 May 25;46(1):35-42.

69. Williams M, Teasdale J, Segal Z, Kabat-Zinn J. The mindful way through depression: Freeing yourself from chronic unhappiness. Guilford Press; 2012 Feb 8.

70. Wang Y. Micro-acupuncture in practice. Elsevier Health Sciences; 2008 May 14.

71. Butterweck V. Mechanism of action of St John's wort in depression: what is known?. CNS drugs. 2003 Jul;17:539-62.

72. Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Molecular psychiatry. 2015 Oct;20(10):1142-50.

73. Zhang Y, Ye F, Zhang T, Lv S, Zhou L, Du D, Lin H, Guo F, Luo C, Zhu S. Structural basis of ketamine action on human NMDA receptors. Nature. 2021 Aug 12;596(7871):301-5.

74. Rachid F. Accelerated transcranial magnetic stimulation for the treatment of patients with depression: A review. Asian Journal of Psychiatry. 2019 Feb 1;40:71-5.

75. Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmöller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology. 2021 Jan 1;132(1):269-306.

76. Zamaria JA. A phenomenological examination of psilocybin use and its positive and persisting aftereffects. Alliant International University; 2014.

77. Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology. 2022 Nov 1;218:109220.

78. Scambler G. Health-related stigma. Sociology of health & illness. 2009 Apr;31(3):441-55.

79. Stuart H. Reducing the stigma of mental illness. Global Mental Health. 2016 Jan;3:e17.

80. Ftouni R, AlJardali B, Hamdanieh M, Ftouni L, Salem N. Challenges of telemedicine during the COVID-19 pandemic: a systematic review. BMC medical informatics and decision making. 2022 Aug 3;22(1):207.

81. Bosworth HB. Medication adherence. Improving patient treatment adherence: a clinician's guide. 2010:68-94.

82. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Therapeutics and clinical risk management. 2008 Feb 29;4(1):269-86.

83. de Zwart PL, Jeronimus BF, de Jonge P. Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review. Epidemiology and psychiatric sciences. 2019 Oct;28(5):544-62.

84. Buus N, Johannessen H, Stage KB. Explanatory models of depression and treatment adherence to antidepressant medication: a qualitative interview study. International journal of nursing studies. 2012 Oct 1;49(10):1220-9.

85. Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs: Innovative strategies. Epilepsy research. 2006 Jun 1;69(3):183-272.

86. Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs. 2012 Jul;72:1313-33.

87. Fabbri C, Serretti A. Clinical application of antidepressant pharmacogenetics: considerations for the design of future studies. Neuroscience letters. 2020 May 1;726:133651.
88. Bruijniks SJ, Meeter M, Lemmens LH, Peeters F, Cuijpers P, Huibers MJ. Temporal and specific pathways of change in cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT) for depression. Behaviour Research and Therapy. 2022 Apr 1;151:104010.
89. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database. 2020;2020:baaa010.
90. Vella SA, Swann C, Batterham M, Boydell KM, Eckermann S, Fogarty A, Hurley D, Liddle SK, Lonsdale C, Miller A, Noetel M. Ahead of the game protocol: a multi-component, community sport-based program targeting prevention, promotion and early intervention for mental health among adolescent males. BMC public health. 2018 Dec;18:1-2.
91. Whitman A, De Lew N, Chappel A, Aysola V, Zuckerman R, Sommers BD. Addressing social determinants of health: Examples of successful evidence-based strategies and current federal efforts. Off Heal Policy. 2022 Apr 1;1:1-30.